Featured


  • Breaking News | Financial Reports
    Veklury Drives 2Q Growth for Gilead

    Veklury Drives 2Q Growth for Gilead

    Veklury (remdesivir) with sales of $829 million offsets loss of exclusivity of Truvada and Atripla in the U.S. with sales down 72% and 42%, respectively.
    07.30.21

  • Financial Reports
    AbbVie

    AbbVie's 2Q Revenue up 34%

    New immunology assets Skyrizi and Rinvoq contribute more than $1 billion of combined sales in the quarter.
    07.30.21

  • Breaking News | Financial Reports
    BMS 2Q Revenues up 16%

    BMS 2Q Revenues up 16%

    Top sellers Revlimid, Eliquis and Opdivo drive growth while established brands were down 64%.
    07.30.21


  • Action Trumps Fear

    Action Trumps Fear

    Move past the fear of failure during the job search by taking the right action steps.
    Online Exclusives Dave Jensen, Contributing Editor 07.30.21

  • Biologics, Proteins, Vaccines | Breaking News | cGMP Manufacture | Industry News
    Global Cell & Gene Therapy Mfg. Market Could Reach $57.4B by 2028

    Global Cell & Gene Therapy Mfg. Market Could Reach $57.4B by 2028

    Market estimated to grow at CAGR of 20% from 2021 to 2028 due to an exponential rise in clinical pipeline along with rising number of regulatory approvals.
    07.30.21

  • Financial Reports
    J&J

    J&J's 2Q Pharma Sales Up 17%

    STELARA and DARZALEX sales drive growth with sales up 34% to $2.3 billion and up 59% to $1.4 billion in the quarter, respectively.
    07.29.21


  • Breaking News | Financial Reports
    Pfizer

    Pfizer's 2Q Revenues Up 92%

    COVID-19 vaccine BNT162b2 contributes $7.8 billion in sales and alliance revenues.
    07.29.21

  • Bio News | Biologics, Proteins, Vaccines | Breaking News | Collaborations & Alliances | Industry News
    CellCAN and CCRM Partner to Launch CATTI

    CellCAN and CCRM Partner to Launch CATTI

    New Institute will tackle gaps in training Canada’s GMP workforce.
    07.29.21

  • Breaking News | Facilities | Industry News
    Regeneron Investing $1.8B in Tarrytown, NY Campus

    Regeneron Investing $1.8B in Tarrytown, NY Campus

    New York's largest biotech company creating an additional 1,000 jobs over five years.
    07.29.21


  • Breaking News | Facilities | Industry News
    Nexus Pharmaceuticals Opens State-of-the-Art Manufacturing Facility

    Nexus Pharmaceuticals Opens State-of-the-Art Manufacturing Facility

    Phase I investment of $100 million supports a new three-story manufacturing facility.
    07.29.21

  • Breaking News | Facilities | Industry News
    Celanese Opens Pharma Drug Delivery Feasibility Lab

    Celanese Opens Pharma Drug Delivery Feasibility Lab

    State-of-the-art R&D lab at Florence, KY site expands technical feasibility capabilities for long-acting delivery of small molecules, biologics and nucleotides.
    07.29.21

  • Bio News | Biologics, Proteins, Vaccines | Breaking News | Collaborations & Alliances | Industry News
    Akston Biosciences, Seppic Ink Commercial Supply Agreement

    Akston Biosciences, Seppic Ink Commercial Supply Agreement

    Deal is for an adjuvant to formulate shelf-stable COVID-19 vaccine at global scale.
    07.29.21

  • Bio News | Biosimilars | Breaking News | cGMP Manufacture | Collaborations & Alliances | Industry News
    Abzena, BioXpress Therapeutics Enter Biosimilar Tie-up

    Abzena, BioXpress Therapeutics Enter Biosimilar Tie-up

    Partnership to support the development and manufacture of biosimilars for global customers.
    07.29.21

  • Breaking News | Industry News | Promotions & Moves
    SCA Pharma Names Scott Luce as CEO

    SCA Pharma Names Scott Luce as CEO

    Luce’s priorities include serving new customer segments and fulfilling the company’s ambitious construction plan to expand capacity.
    07.29.21

  • Breaking News | Industry News | Promotions & Moves
    Sterling Pharma Solutions Appoints Ian Baxendale to Lead Team at Dudley, UK Site

    Sterling Pharma Solutions Appoints Ian Baxendale to Lead Team at Dudley, UK Site

    Baxendale has over 20 years of academic and industrial experience within organic synthesis.
    07.29.21